Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 447

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 447
---
 CONSOLIDATED FINANCIAL STATEMENTS
(Stated in U.S. Dollars)

1. ORGANIZATION

The consolidated financial statements include the financial statements of Aptorum Group Limited (the “Company”) and its subsidiaries. The Company and its subsidiaries are hereinafter collectively referred to as the “Group”.

The Company, formerly known as APTUS Holdings Limited and STRIKER ASIA OPPORTUNITIES FUND CORPORATION, is a company incorporated on under the laws of the Cayman Islands with limited liability.

The Company researches and develops life science and biopharmaceutical products within its wholly-owned subsidiary, Aptorum Therapeutics Limited, formerly known as APTUS Therapeutics Limited (“Aptorum Therapeutics”) and its indirect subsidiary companies.

Below summarizes the list of the major subsidiaries consolidated as of December 31, 2024:

| Name                                 
 Aptorum Therapeutics Limited (“ATL”) 
 APTUS MANAGEMENT LIMITED             |     | Incorporation  
 date           
 June 30, 2016  
 May 16, 2017   |     | Ownership 
 100%      
 100%      |     | Place of       
 incorporation  
 Cayman Islands 
 Hong Kong      |     | Principle activities                                                            
 Research and development of life science and biopharmaceutical products         
 Provision of management services to its holding company and fellow subsidiaries |
|:-------------------------------------|:----|:---------------|:----|:----------|:----|:---------------|:----|:--------------------------------------------------------------------------------|
| Paths Innovations Limited            |     | April 15, 2019 |     | 100%      |     | Cayman Islands |     | Investment holding company                                                      |
| Paths Diagnostics Pte. Limited       |     | June 5, 2019   |     | 75%       |     | Singapore      |     | Research and development of life science and biopharmaceutical products         |
| Acticule Life Sciences Limited       |     | June 30, 2017  |     | 80%       |     | Cayman Islands |     | Research and development of life science and biopharmaceutical products         |

2. GOING CONCERN The Group reported a net loss of $ 4,157,737and net operating cash outflow of $ 1,189,734for the year ended December 31, 2024. In addition, the Group had an accumulated deficit of $ 72,429,528as of December 31, 202